A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Reteplase and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Reteplase and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Abciximab (Primary) ; Reteplase (Primary)
  • Indications Cardiogenic shock; Embolism and thrombosis; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms FINESSE
  • Sponsors Centocor
  • Most Recent Events

    • 05 Dec 2008 Status changed from active, no longer recruiting to completed.
    • 30 Dec 2006 Status changed from recruiting to in progress.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top